Skip to main content

VISIOCYT SCREENING: A DISRUPTIVE ARTIFICIAL INTELLIGENCE SOLUTION FOR BLADDER CANCER SCREENING

Project description

A pioneering screening tool for early detection of bladder cancer could save millions

The difference between early and late diagnosis of cancer can mean the difference between life and death. Unlike a routine PAP test for cervical cancer or a colonoscopy for colon cancer, there is currently no effective screening tool for bladder cancer and late diagnosis can have lethal consequences. VISIOCYT has developed a simple software solution that evaluates standard clinical cytology slides. A proprietary method for preparation, staining and observation of cells is coupled with an image processing algorithm to detect the presence of localised fluorescence associated with malignancy. Deep learning algorithms allow the software to learn from the data without being explicitly programmed. EU funding is supporting commercialisation of this reproducible and high throughput technology for early bladder cancer detection.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

VITADX INTERNATIONAL
Net EU contribution
€ 50 000,00
Address
74 F Rue De Paris
35000 Rennes
France

See on map

Region
Bretagne Bretagne Ille-et-Vilaine
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 21 429,00